(Q35739525)

English

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer

scientific article published on 10 January 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H M Coley

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

N A M Safuwan

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

P Chivers

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

E Papacharalbous

4

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

T Giannopoulos

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

S Butler-Manuel

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

K Madhuri

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

D P Lovell

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

T Crook

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

language of work or name

0 references

publication date

10 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

106

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

482-489

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Epigenetics as a mechanism driving polygenic clinical drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

The expression of Cdk inhibitors p27kip1 and p57kip2 in mouse placenta and human choriocarcinoma JEG-3 cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Cooperation between the Cdk inhibitors p27(KIP1) and p57(KIP2) in the control of tissue growth and development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

12 July 2018

Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.566

21 January 2018

The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.566

21 January 2018

Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

25 September 2018

Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3273354

25 September 2018

Expression of cell cycle regulators p57KIP2, cyclin D1, and cyclin E in epithelial ovarian tumors and survival

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.566

21 January 2018

Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22233925

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22233925

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.2011.566

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35739525&oldid=2197667605"